OSTX — OS Therapies Inc

—
NYSE · Health Care · Pharmaceuticals · CIK 1795091 ·
Last close
$0.74
Market Cap
$34.86M
52W High
$2.25
52W Low
$0.58
ADV30
636,082
Next earnings
2026-11-17

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -9,034,658 -11,279,162 8,107,707 431,816 25,076,884
Jun 2026 0 — -8,575,612 -8,632,386 9,897,313 205,035 21,811,948
Mar 2026 0 — -10,167,938 -10,396,831 7,299,236 917,552 18,123,474
Dec 2025 0 — -11,987,892 -13,460,833 6,839,534 269,830 12,935,165

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-18,532,848
Investing CF
$0
Financing CF
$15,935,870
CapEx
$-466,423
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.87
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-86,215,436
Inventory
—
Receivables
$3,097,825
ST Investments
—
EBIT TTM
$-39,288,655
Pretax Income TTM
$-39,369,580
Interest Exp TTM
$80,925
Analysts
4

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -28,705,701 -28,753,844 6,839,534 12,935,165 -6,095,631 -14,238,576
Dec 2024 0 -6,813,846 -8,882,938 5,538,797 8,805,335 -3,266,538 -7,282,295
Dec 2023 0 -4,342,645 -7,791,582 798,082 24,814,297 -24,016,215 -3,006,967
Dec 2022 0 -4,446,299 -6,254,685 509,105 18,066,333 -17,557,228 -3,792,580
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$210
NetIncome TTM
$-39,369,580
OpCashFlow TTM
—
Assets (Latest)
$9,897,313
Forward EPS
$0.35

Peers — same industry

TickerNameMarket CapLastDaily %
BMEA Biomea Fusion, Inc. $35.47M $0.49 —
ATHE ALTERITY THERAPEUTICS LTD $33.96M $1.87 —
GRCE Grace Therapeutics, Inc. $36.18M $1.72 —
SER Serina Therapeutics, Inc. $36.27M $1.37 —
CNTB Connect Biopharma Holdings Ltd $36.45M $0.58 —

News headlines (Yahoo Finance, 1h cache)

OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company
2026-11-13 13:30 · Yahoo
OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
2026-11-10 13:15 · Yahoo
OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial
2026-11-05 13:00 · Yahoo
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
2026-10-19 12:30 · Yahoo
Rubenstein Public Relations Named Agency of Record for OS Therapies
2026-10-08 13:22 · Yahoo
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
2026-10-07 12:30 · Yahoo
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
2026-10-06 12:30 · Yahoo
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
2026-10-01 12:30 · Yahoo
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
2026-09-24 12:22 · Yahoo
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
2026-09-21 10:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.